Hande Arslan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hande Arslan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Feyza Donmez
Psychiatry Department, Kutahya Health Sciences University, School of Medicine
1 shared publication - Kader Semra Karatas
Department of Psychiatry, School of Medicine, Kutahya Health Sciences University, Kutahya, Turkey
1 shared publication - Merve Akkuş
Department of Psychiatry, Kutahya Health Sciences University, Faculty of Medicine, Kutahya, Turkey
1 shared publication - Onur Gökçen
Department of Psychiatry, Faculty of Medicine, Kutahya Health Sciences University, Kutahya, Turkey
1 shared publication - Samin Soudkhah
Psychiatry Department, Kutahya Health Sciences University, School of Medicine
1 shared publication - Sibel Haci
Psychiatry Department, Kutahya Health Sciences University, School of Medicine
1 shared publication
Latest Publications
- 23 January 2026
- Published by Taylor & Francis in Journal of Addictive Diseases
- p. 1-11
Clinical and inflammatory profiles in substance use disorder: gender, substance type, and comorbidity in a single-center cross-sectional study in Turkey
Substance use disorder (SUD) is associated with systemic inflammation and cognitive vulnerability. Peripheral biomarkers may help characterize biological risk across substances and comorbidities. Turkey has experienced a recent rise in methamphetamine and pregabalin misuse, underscoring the need for biomarker-based clinical profiling. A total of 321 inpatients were evaluated in a single inpatient addiction treatment unit in Turkey (2019-2025). Exclusion criteria included severe somatic disease, preexisting psychiatric diagnoses, and incomplete records. Admission data included demographics, primary substance, DSM-5 comorbidities, biomarkers (C-reactive protein [CRP], neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Systemic Immune-Inflammation Index, Hemoglobin × Albumin/Leukocyte × Platelet Index, Inflammatory Burden Index [IBI]). Analyses used appropriate parametric/non-parametric tests, analysis of covariance, and logistic regression adjusted for age, sex, and comorbidities. IBI and CRP differed significantly across substance groups, with higher inflammatory burden among methamphetamine, alcohol, and MDMA users. After multiple-comparison correction, IBI remained statistically significant, whereas CRP required cautious interpretation. Longer duration of use correlated with higher inflammatory burden. Depressive (14.6%) and anxiety disorders (16.2%) were the most common comorbidities. Bipolar disorder, although infrequent, clustered with higher inflammatory markers. Gender patterns reflected international trends, with greater alcohol/cannabis use in male and earlier, faster dependence progression in female. Multivariate models showed that methamphetamine and alcohol independently predicted elevated IBI after adjustment. IBI and CRP appear to be the most sensitive indicators of systemic inflammation in SUD, particularly in stimulant and alcohol users. Elevation of IBI supports its potential role as a cognition-related biomarker. Findings highlight biological heterogeneity across substances, genders, and comorbidities, and emphasize the need for future prospective studies with neurocognitive testing and structured tobacco documentation.
- 23 January 2026
- Published by Taylor & Francis in Journal of Addictive Diseases
- p. 1-11
Clinical and inflammatory profiles in substance use disorder: gender, substance type, and comorbidity in a single-center cross-sectional study in Turkey
Substance use disorder (SUD) is associated with systemic inflammation and cognitive vulnerability. Peripheral biomarkers may help characterize biological risk across substances and comorbidities. Turkey has experienced a recent rise in methamphetamine and pregabalin misuse, underscoring the need for biomarker-based clinical profiling. A total of 321 inpatients were evaluated in a single inpatient addiction treatment unit in Turkey (2019-2025). Exclusion criteria included severe somatic disease, preexisting psychiatric diagnoses, and incomplete records. Admission data included demographics, primary substance, DSM-5 comorbidities, biomarkers (C-reactive protein [CRP], neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Systemic Immune-Inflammation Index, Hemoglobin × Albumin/Leukocyte × Platelet Index, Inflammatory Burden Index [IBI]). Analyses used appropriate parametric/non-parametric tests, analysis of covariance, and logistic regression adjusted for age, sex, and comorbidities. IBI and CRP differed significantly across substance groups, with higher inflammatory burden among methamphetamine, alcohol, and MDMA users. After multiple-comparison correction, IBI remained statistically significant, whereas CRP required cautious interpretation. Longer duration of use correlated with higher inflammatory burden. Depressive (14.6%) and anxiety disorders (16.2%) were the most common comorbidities. Bipolar disorder, although infrequent, clustered with higher inflammatory markers. Gender patterns reflected international trends, with greater alcohol/cannabis use in male and earlier, faster dependence progression in female. Multivariate models showed that methamphetamine and alcohol independently predicted elevated IBI after adjustment. IBI and CRP appear to be the most sensitive indicators of systemic inflammation in SUD, particularly in stimulant and alcohol users. Elevation of IBI supports its potential role as a cognition-related biomarker. Findings highlight biological heterogeneity across substances, genders, and comorbidities, and emphasize the need for future prospective studies with neurocognitive testing and structured tobacco documentation.